Prognostic Role of Serum Amino Acids in Head and Neck Cancer.
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
02
2020
revised:
18
08
2020
accepted:
14
09
2020
entrez:
21
10
2020
pubmed:
22
10
2020
medline:
28
7
2021
Statut:
epublish
Résumé
Serum amino acid (AA) profiles represent a valuable tool in the metabolic assessment of cancer patients; still, information on the AA pattern in head and neck cancer (HNC) patients is insufficient. The aim of the study was to assess whether serum AA levels were associated with the stage of neoplastic disease and prognosis in primary HNC patients. Two hundred and two primary HNC patients were included in the study. Thirty-one AAs and derivatives were measured in serum through an ultraperformance liquid chromatography-mass spectrometry (UPLC-MS). The association between AA concentrations and the stage (advanced versus early) of HNC was estimated using a multivariable logistic regression model. A multivariable Cox regression model was used to evaluate the prognostic significance of each AA. At the multivariable logistic regression analysis, increased levels of alpha-aminobutyric acid, aminoadipic acid, histidine, proline, and tryptophan were associated with a reduced risk of advanced stage HNC, while high levels of beta-alanine, beta-aminobutyric acid, ethanolamine, glycine, isoleucine, 4-hydroxyproline, and phenylalanine were associated with an increased risk of advanced stage HNC. Furthermore, at multivariate analysis, increased levels of alpha-aminobutyric acid were associated with increased overall survival (OS), while high levels of arginine, ethanolamine, glycine, histidine, isoleucine, 4-hydroxyproline, leucine, lysine, 3-methylhistidine, phenylalanine, and serine were associated with decreased OS. Our study suggests that AA levels are associated with the stage of disease and prognosis in patients with HNC. More study is necessary to evaluate if serum AA levels may be considered a hallmark of HNC and prove to be clinically useful markers of disease status and prognosis in HNC patients.
Identifiants
pubmed: 33082883
doi: 10.1155/2020/2291759
pmc: PMC7556086
doi:
Substances chimiques
Amino Acids
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2291759Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2020 Gabriella Cadoni et al.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest.
Références
Cancers (Basel). 2019 May 15;11(5):
pubmed: 31096630
Cell Metab. 2016 Jan 12;23(1):27-47
pubmed: 26771115
Science. 1955 Sep 16;122(3168):501-14
pubmed: 13255879
Cancer. 2005 Jan 15;103(2):284-92
pubmed: 15593092
Int J Med Sci. 2017 Jan 1;14(1):1-12
pubmed: 28138303
Oxid Med Cell Longev. 2017;2017:4829180
pubmed: 28785375
Eur J Epidemiol. 2016 Apr;31(4):369-83
pubmed: 25930054
Dev Cell. 2016 Mar 7;36(5):540-9
pubmed: 26954548
Eur J Epidemiol. 2018 Dec;33(12):1205-1218
pubmed: 29779202
Oral Oncol. 2012 Dec;48(12):1227-35
pubmed: 22917549
Amino Acids. 2011 Apr;40(4):1053-63
pubmed: 20697752
Science. 2012 May 25;336(6084):1040-4
pubmed: 22628656
Oncotarget. 2017 Apr 4;8(14):23955-23977
pubmed: 28177894
Int J Radiat Biol. 2019 Apr;95(4):480-492
pubmed: 29667485
AJNR Am J Neuroradiol. 1997 Jun-Jul;18(6):1057-72
pubmed: 9194433
Am J Clin Nutr. 2010 Nov;92(5):1151-6
pubmed: 20881073
BMC Cancer. 2013 Feb 15;13:77
pubmed: 23409863
Clinics (Sao Paulo). 2012 Oct;67(10):1225-7
pubmed: 23070352
Nutr Diabetes. 2017 Mar 13;7(3):e249
pubmed: 28287627
BBA Clin. 2016 Dec 18;7:8-15
pubmed: 28053877
Nutrients. 2016 Jul 01;8(7):
pubmed: 27376324
Int J Cancer. 2018 Jul 1;143(1):32-44
pubmed: 29405297
Int J Biochem Cell Biol. 2012 Nov;44(11):1852-61
pubmed: 22743333
Amino Acids. 2013 Oct;45(4):719-33
pubmed: 23836420
Clin Cancer Res. 2018 Jan 15;24(2):474-485
pubmed: 29084919
Cancer Res. 2001 Apr 1;61(7):2911-6
pubmed: 11306467
Endocrinol Metab (Seoul). 2019 Sep;34(3):234-246
pubmed: 31565875
Cells. 2019 May 09;8(5):
pubmed: 31075822
Cancer Genomics Proteomics. 2013 Sep-Oct;10(5):233-8
pubmed: 24136976
Nat Commun. 2016 Apr 18;7:11321
pubmed: 27089238
Nat Rev Cancer. 2013 Aug;13(8):572-83
pubmed: 23822983
Lancet. 2008 May 17;371(9625):1695-709
pubmed: 18486742
Oncogene. 2016 Sep 22;35(38):4957-72
pubmed: 27109103
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Clin Invest. 2013 Oct;123(10):4309-17
pubmed: 24091325
Front Oncol. 2018 Mar 16;8:67
pubmed: 29616189
Nutr Cancer. 1998;30(2):144-7
pubmed: 9589433
J Clin Med. 2019 Jul 10;8(7):
pubmed: 31295923